Abstract
Background Recent data indicates high prevalence of post-traumatic stress disorder (PTSD) in bipolar disorder (BD). PTSD may play a role in poor treatment outcomes and quality of life for people with BD. Despite this, few studies have examined the pharmacological treatment interventions and outcomes for this comorbidity. This systematic review will bring together currently available evidence regarding the impact of comorbid PTSD on pharmacological treatment outcomes in adults with BD.
Methods A systematic search of Embase, MEDLINE Complete, PsycINFO, and the Cochrane Central Register of Controlled Trials (CENTRAL) will be conducted to identify randomised and non-randomised studies of pharmacological interventions for adults with diagnosed bipolar disorder and PTSD. Data will be screened and extracted by two independent reviewers. Literature will be searched from the creation of the databases until April 1 2021. Risk of bias will be assessed using the Newcastle-Ottawa Scale and the Cochrane Collaborations Risk of Bias tool. A meta-analysis will be conducted if sufficient evidence is identified in the systematic review. The meta-analysis will employ a random-effects model and be evaluated using the I2 statistic.
Discussion This review and meta-analysis will be the first to systematically explore and integrate the available evidence on the impact of PTSD on pharmacological treatments and outcome in those with BD. The results and outcomes of this systematic review will provide directions for future research and be published in relevant scientific journals and presented at research conferences.
Systematic review registration The protocol has been registered at the International Prospective Register of Systematic Reviews (PROSPERO; registration number: CRD42020182540).
Competing Interest Statement
SER has received grant/research support from Deakin University. ALW has received grant/research support from Deakin University. OMD is a R.D. Wright Biomedical NHMRC Career Development Fellow (APP1145634) and has received grant support from the Brain and Behavior Foundation, Simons Autism Foundation, Stanley Medical Research Institute, Deakin University, Lilly, NHMRC and ASBDD/Servier. She has also received in kind support from BioMedica Nutracuticals, NutritionCare and Bioceuticals. DRS is supported by an NHMRC Medical Research Future Fund (1200214). BEK has received research support from Australian Rotary Health, the Australian Government Research Training Program, and the International Society for the Study of Personality Disorders. MMA has received grant/research support from Deakin University, Australasian Society for Bipolar Depressive Disorders, Lundbeck, Australian Rotary Health, Ian Parker Bipolar Research Fund and Cooperative Research Centre for Mental Health and PDG Geoff and Betty Betts Award from Rotary Club of Geelong. MB has received grant/research support from the NIH, Cooperative Research Centre, Simons Autism Foundation, Cancer Council of Victoria, Stanley Medical Research Foundation, Medical Benefits Fund, National Health and Medical Research Council, Medical Research Futures Fund, Beyond Blue, Rotary Health, A2 milk company, Meat and Livestock Board, Woolworths, Avant and the Harry Windsor Foundation, has been a speaker for Astra Zeneca, Lundbeck, Merck, Pfizer, and served as a consultant to Allergan, Astra Zeneca, Bioadvantex, Bionomics, Collaborative Medicinal Development, Lundbeck Merck, Pfizer and Servier. AT has received travel or grant support from NHMRC, AMP Foundation, Stroke Foundation, Hunter Medical Research Institute, Helen Macpherson Smith Trust, Schizophrenia Fellowship NSW, SMHR, ISAD, the University of Newcastle and Deakin University.
Funding Statement
This study did not receive funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Author email addresses: samantha.russell{at}deakin.edu.au, anna.wrobel{at}deakin.edu.au, david.skvarc{at}deakin.edu.au, o.dean{at}deakin.edu.au, bianca.kavanagh{at}deakin.edu.au, michael.berk{at}deakin.edu.au.
Data Availability
This is a systematic review protocol and therefore no data is available.
List of abbreviations
- BD
- bipolar disorder
- PTSD
- post-traumatic stress disorder
- CENTRAL
- Cochrane Central Register of Controlled Trials
- BDI
- Bipolar Disorder 1
- SSRI
- Selective serotonin reuptake inhibitors
- NICE
- National Institute for Health and Care Excellence
- WHO
- World Health Organization
- PICO
- Populations, Intervention, Comparator and Outcome
- PRISMA
- P Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols
- CIDI
- The Composite International Diagnostic Interview
- SCID
- Structured Clinical Interview for the DSM
- MINI
- The Mini International Neuropsychiatric Interview
- CAPS
- Clinician administered PTSD Scale
- PDS
- Posttraumatic Diagnostic Scale
- PCL5
- PTSD Checklist for DSM-5
- RCT
- Randomised controlled trials
- MeSH
- Medical subject headings
- MADRS
- Montgomery Åsberg Rating Scale
- BDRS
- Bipolar Depression Rating Scale
- YMRS
- Young Mania Rating Scale
- BISS
- Bipolar Inventory of Symptom Scale
- Q-LES-Q
- Quality of Life Enjoyment and Satisfaction Questionnaire
- CGI-BP
- Clinical Global Impressions-Bipolar Disorder
- CGI-I
- Clinical Global Impressions – Improvement
- SOFAS
- Social and Occupational Functioning Assessment Scale
- LIFE-RIFT
- Longitudinal Interval Follow-up Evaluation – Range of Impaired Functioning Tool
- GRADE
- the Grades of Recommendation, Assessment, Development and Evaluation
- JBI
- Joanna Briggs Institute
- CI
- Confidence intervals
- SMD
- Standard mean difference
- CMA
- Comprehensive Meta-Analysis